Alar Pharmaceuticals Statistics

Total Valuation

Alar Pharmaceuticals has a market cap or net worth of TWD 9.15 billion. The enterprise value is 6.73 billion.

Market Cap	9.15B
Enterprise Value	6.73B

Important Dates

The next estimated earnings date is Monday, March 3, 2025.

Earnings Date	Mar 3, 2025
Ex-Dividend Date	n/a

Share Statistics

Alar Pharmaceuticals has 66.80 million shares outstanding. The number of shares has increased by 11.95% in one year.

Current Share Class	n/a
Shares Outstanding	66.80M
Shares Change (YoY)	+11.95%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	25.42%
Owned by Institutions (%)	5.04%
Float	35.25M

Valuation Ratios

The trailing PE ratio is 21.81 and the forward PE ratio is 238.26.

PE Ratio	21.81
Forward PE	238.26
PS Ratio	18.42
PB Ratio	3.71
P/TBV Ratio	3.71
P/FCF Ratio	42.02
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 17.49, with an EV/FCF ratio of 30.89.

EV / Earnings	16.79
EV / Sales	14.18
EV / EBITDA	17.49
EV / EBIT	17.66
EV / FCF	30.89

Financial Position

The company has a current ratio of 45.14, with a Debt / Equity ratio of 0.00.

Current Ratio	45.14
Quick Ratio	44.92
Debt / Equity	0.00
Debt / EBITDA	0.00
Debt / FCF	0.00
Interest Coverage	11,346.18

Financial Efficiency

Return on equity (ROE) is 27.11% and return on invested capital (ROIC) is 16.30%.

Return on Equity (ROE)	27.11%
Return on Assets (ROA)	15.10%
Return on Capital (ROIC)	16.30%
Revenue Per Employee	21.56M
Profits Per Employee	18.21M
Employee Count	22
Asset Turnover	0.30
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -34.98% in the last 52 weeks. The beta is 0.07, so Alar Pharmaceuticals's price volatility has been lower than the market average.

Beta (5Y)	0.07
52-Week Price Change	-34.98%
50-Day Moving Average	157.55
200-Day Moving Average	226.30
Relative Strength Index (RSI)	32.95
Average Volume (20 Days)	200,956

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Alar Pharmaceuticals had revenue of TWD 474.29 million and earned 400.72 million in profits. Earnings per share was 6.28.

Revenue	474.29M
Gross Profit	472.26M
Operating Income	385.77M
Pretax Income	421.32M
Net Income	400.72M
EBITDA	388.20M
EBIT	385.77M
Earnings Per Share (EPS)	6.28

Full Income Statement

Balance Sheet

The company has 2.42 billion in cash and 424,000 in debt, giving a net cash position of 2.42 billion or 36.29 per share.

Cash & Cash Equivalents	2.42B
Total Debt	424,000
Net Cash	2.42B
Net Cash Per Share	36.29
Equity (Book Value)	2.47B
Book Value Per Share	36.93
Working Capital	2.38B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 220.54 million and capital expenditures -2.78 million, giving a free cash flow of 217.77 million.

Operating Cash Flow	220.54M
Capital Expenditures	-2.78M
Free Cash Flow	217.77M
FCF Per Share	3.26

Full Cash Flow Statement

Margins

Gross margin is 99.57%, with operating and profit margins of 81.34% and 84.49%.

Gross Margin	99.57%
Operating Margin	81.34%
Pretax Margin	88.83%
Profit Margin	84.49%
EBITDA Margin	81.85%
EBIT Margin	81.34%
FCF Margin	45.91%

Dividends & Yields

This stock pays an annual dividend of 1.50, which amounts to a dividend yield of 1.09%.

Dividend Per Share	1.50
Dividend Yield	1.09%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	25.00%
Buyback Yield	-11.95%
Shareholder Yield	-10.85%
Earnings Yield	4.59%
FCF Yield	2.38%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Alar Pharmaceuticals has an Altman Z-Score of 170.

Altman Z-Score	170
Piotroski F-Score	n/a